feMAle fundRaisIng leAdership in advanced techNologies for brAin diSorders

Información del proyecto

MARIANAS

Identificador del acuerdo de subvención: 101114214

DOI

10.3030/101114214

Proyecto cerrado

Fecha de la firma de la CE 1 Junio 2023

Fecha de inicio 1 Julio 2023

Fecha de finalización 31 Diciembre 2023

Financiado con arreglo a

• European innovation ecosystems

Coste total

Sin datos

Aportación de la UE

€ 75 000,00

Coordinado por

ALPHA BRAIN TECHNOLOGIES
Netherlands

Periodic Reporting for period 1 - MARIANAS (feMAle fundRaisIng leAdership in advanced techNologies for brAin diSorders)

Período documentado: 2023-07-01 hasta 2023-12-31

Resumen del contexto y de los objetivos generales del proyecto

Alpha Brain Technologies (ABT) stands at the forefront of innovation with AI-powered devices designed to address neurological anomalies in real-time. This breakthrough opens up new avenues for transforming treatment approaches and holds the potential to proactively prevent neurological disorders. Driven by a personal quest, the first device predicts seizures before their onsets with the goal of stopping the seizures before they happen. Epilepsy is one of the largest neurological disorders, affecting 6 million Europeans; epilepsy causes unpredictable seizures and presenting various symptoms. This condition significantly reduces the quality of life and can even lead to premature death. The EU-funded MARIANAS project will build upon ABT’s past achievements by engaging stakeholders, including patients and caregivers, in a fundraising campaign to conduct clinical trials and ultimately commercialise the solution.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

The project achieved the following main activities:1. Improved business plan including a detailed regulatory pathway; 2. Improved stakeholder’s identification & engagement; 3. Produced a three-year communication & marketing plan 4. Drew up an advanced financial plan to attract future funding.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Epilepsy is a severe, chronic, and unpredictable neurological disease affecting over 70 million people worldwide. At present, epileptic patients have a 1.6 to 3 times higher chance of dying prematurely due to fatal seizures or accidents related to them. Prediction of seizures allows for taking several preventative measures to improve the clinical outcome. These measures are: 1. Patient entering a safe position and stopping a ‘dangerous’ activity such as showering, riding a cycle, or drinking a hot beverage which is important for preventing accidents/death); 2. Stopping seizures from happening with the use of existing solutions that are not currently used for prevention; 3.Informing caregivers and medical personnel before the start of a seizure. Our key need lies in further demonstration of the innovation via clinical studies (planned for 2024 with 6 epilepsy centers around Europe), and subsequently a funding round.